Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10755MR)

This product GTTS-WQ10755MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10755MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11417MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ6568MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ13321MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ4172MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ14304MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ12437MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ2977MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ5150MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW